Latest news
- Business26 April 2024
Adalvo Recognizes World IP Day 2024: Prioritizing Health and Well-being
Adalvo acknowledges and participates in World IP Day 2024, joining the global community in celebrating innovation and creativity in intellectual property (IP). This year's theme, "šš šš§š šš”š šššš¬: šš®š¢š„šš¢š§š ...
- Business22 April 2024
Adalvo Introduces Apalutamide to its Oncology Portfolio
Adalvo is excited to announceĀ the introduction ofĀ Apalutamide to our Oncology Portfolio. Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a...
- Business17 April 2024
Adalvo advances on Ceftazidime + Avibactam
Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets.Ā Based on the...
- Achievements15 April 2024
Adalvo Sets New Performance Record in March: Highest Batch Release Achieved
Adalvo proudly announces a significant milestone in its operational performance, setting a new record by releasing aĀ total of 221 batches during March 2024, surpassing previous benchmarks by 42%. This achievement showcases...
- Business12 April 2024
Pregabalin Prolonged Release Tablets Launched in Germany
Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European...
- Business09 April 2024
Mirabegron/Solifenacin PR Tablets Added To Adalvo's Product List
Adalvo proudly announces the addition of Mirabegron/Solifenacin Prolonged Release Tablets to our product list,Ā set to be submitted for regulatory approval in Q1 2025. Developed in collaboration with one of our strategic...
- Business08 April 2024
Aztiq Acquires 100% Ownership of Adalvo from PTT, Backed by Investor Metric Capital Partners to Accelerate Further Growth
Aztiq, a prominent healthcare investor led by Founder and Chairman RĆ³bert Wessman, has finalized an agreement in Q1 2024 with Innobic (Asia) Company Limited (āInnobicā), the life science arm of...
- Business05 April 2024
Adalvo Restarts DCP Procedure for Empagliflozin Film-Coated Tablets
Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024. Our product has...
- Business04 April 2024
Adalvo Launches Desmopressin in Multiple Countries Across Europe
Adalvo is thrilled to announce the successful launch of DesmopressinĀ in multiple countries across Europe, in collaboration with key strategic partners. Developed based on the reference brand Minirin Melt from Ferring, Desmopressin...
- Business27 March 2024
Adalvo Announces Successful Completion of Pilot BE Study for Fidaxomicin
Adalvo is delighted to announce the successful completion of the FED and Fasting Pilot BE Study for Fidaxomicin Film Coated Tablets 200mg. Developed in collaboration with one of our strategic partners,...
- Business26 March 2024
Alectinib Tablets Added To Adalvo's Product List
Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tabletsĀ to our product list. Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as...
- Business20 March 2024
Adalvo Restarts Regulatory Procedures for Ethinylestradiol + DrospirenoneĀ DCP
Adalvo is pleased to announce the restart of the DCP procedure forĀ Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024. Based on the reference brand...
- Business15 March 2024
Lenvatinib Oral Solution Added To Adalvo's Product Portfolio
Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral SolutionĀ to our product portfolio. Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid...
- Business13 March 2024
Adalvo Restarts Regulatory Procedures for Dalbavancin DCP with Anticipated European Approval in May 2024
Adalvo is delighted to announce the restart of the DCP procedure for DalbavancinĀ powder, with an estimated approval date in May 2024. This antibiotic niche product has been developed based on...
- Business08 March 2024
Adalvo Receives Marketing Authorization Approval for Pomalidomide Hard Capsules in Israel
Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel. Our product, based on the reference brand Imnovid, is indicated for the...
- Achievements06 March 2024
Adalvo Joins Medicines For Europe Association
Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector.Ā Ā As a member, Adalvo will play a pivotal role in shaping the future...
- Business01 March 2024
Adalvo Restarts Regulatory Procedures for Liraglutide DCP with Anticipated European Approval in June 2024
Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024. As a generic and bioequivalent...
- Business29 February 2024
Adalvo Stands in Solidarity on Rare Disease Day
Adalvo stands in solidarity with the global community on Rare Disease Day, today February 29th, remindingĀ us of the profound challenges faced by millions worldwide battling rare diseases, where access to...
- Business23 February 2024
Adalvo is among the first to register Mirabegron in European Markets
Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets. This product has been developed in collaboration with one of our strategic partners,...